Your browser doesn't support javascript.
loading
Immunologic characterization of a rhesus macaque H1N1 challenge model for candidate influenza virus vaccine assessment.
Skinner, Jason A; Zurawski, Sandra M; Sugimoto, Chie; Vinet-Oliphant, Heather; Vinod, Parvathi; Xue, Yaming; Russell-Lodrigue, Kasi; Albrecht, Randy A; García-Sastre, Adolfo; Salazar, Andres M; Roy, Chad J; Kuroda, Marcelo J; Oh, SangKon; Zurawski, Gerard.
Affiliation
  • Skinner JA; Baylor Institute for Immunology Research, Dallas, Texas, USA.
  • Zurawski SM; Baylor Institute for Immunology Research, Dallas, Texas, USA.
  • Sugimoto C; Tulane National Primate Research Center, Covington, Louisiana, USA.
  • Vinet-Oliphant H; Tulane National Primate Research Center, Covington, Louisiana, USA.
  • Vinod P; Baylor Institute for Immunology Research, Dallas, Texas, USA.
  • Xue Y; Baylor Institute for Immunology Research, Dallas, Texas, USA.
  • Russell-Lodrigue K; Tulane National Primate Research Center, Covington, Louisiana, USA.
  • Albrecht RA; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • García-Sastre A; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Salazar AM; Oncovir, Inc., Washington, DC, USA.
  • Roy CJ; Tulane National Primate Research Center, Covington, Louisiana, USA.
  • Kuroda MJ; Tulane National Primate Research Center, Covington, Louisiana, USA.
  • Oh S; Baylor Institute for Immunology Research, Dallas, Texas, USA.
  • Zurawski G; Baylor Institute for Immunology Research, Dallas, Texas, USA gerardz@baylorhealth.edu.
Clin Vaccine Immunol ; 21(12): 1668-80, 2014 Dec.
Article de En | MEDLINE | ID: mdl-25298110
ABSTRACT
Despite the availability of annually formulated vaccines, influenza virus infection remains a worldwide public health burden. Therefore, it is important to develop preclinical challenge models that enable the evaluation of vaccine candidates while elucidating mechanisms of protection. Here, we report that naive rhesus macaques challenged with 2009 pandemic H1N1 (pH1N1) influenza virus do not develop observable clinical symptoms of disease but develop a subclinical biphasic fever on days 1 and 5 to 6 postchallenge. Whole blood microarray analysis further revealed that interferon activity was associated with fever. We then tested whether type I interferon activity in the blood is a correlate of vaccine efficacy. The animals immunized with candidate vaccines carrying hemagglutinin (HA) or nucleoprotein (NP) exhibited significantly reduced interferon activity on days 5 to 6 postchallenge. Supported by cellular and serological data, we conclude that blood interferon activity is a prominent marker that provides a convenient metric of influenza virus vaccine efficacy in the subclinical rhesus macaque model.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Vaccins antigrippaux / Infections à Orthomyxoviridae / Grippe humaine / Sous-type H1N1 du virus de la grippe A / Anticorps antiviraux Limites: Animals / Humans Langue: En Journal: Clin Vaccine Immunol Sujet du journal: ALERGIA E IMUNOLOGIA / TECNICAS E PROCEDIMENTOS DE LABORATORIO Année: 2014 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Vaccins antigrippaux / Infections à Orthomyxoviridae / Grippe humaine / Sous-type H1N1 du virus de la grippe A / Anticorps antiviraux Limites: Animals / Humans Langue: En Journal: Clin Vaccine Immunol Sujet du journal: ALERGIA E IMUNOLOGIA / TECNICAS E PROCEDIMENTOS DE LABORATORIO Année: 2014 Type de document: Article Pays d'affiliation: États-Unis d'Amérique
...